Burning Rock Biotech (Burning Rock Biotech) Gross-Profit-to-Asset % : 27.25% (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Burning Rock Biotech's annualized Gross Profit for the quarter that ended in Sep. 2023 was $47.09 Mil. Burning Rock Biotech's average Total Assets over the quarter that ended in Sep. 2023 was $172.85 Mil. Therefore, Burning Rock Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 27.25%.

Burning Rock Biotech Gross-Profit-to-Asset % Historical Data

The historical data trend for Burning Rock Biotech's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech Gross-Profit-to-Asset % Chart

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

36.24

44.54

18.18

14.95

18.62

Burning Rock Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															23.59	24.50	26.46	28.65	27.25

Competitive Comparison of Burning Rock Biotech's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Burning Rock Biotech's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Gross-Profit-to-Asset % falls into.

Burning Rock Biotech Gross-Profit-to-Asset % Calculation

Burning Rock Biotech's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	54.512	/	( (357.745	+	227.702)	/ 2 )
	=	54.512	/	292.7235
	=	18.62 %

Burning Rock Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	47.092	/	( (185.823	+	159.869)	/ 2 )
	=	47.092	/	172.846
	=	27.25 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Burning Rock Biotech Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech (Burning Rock Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BNR:UK 6BUA:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.